Zirvi v. Flatley

Background

The plaintiffs—scientists Monib Zirvi, Matthew Lubin, Maria Kempe, and Norman Gerry—claimed that the defendants, including scientists, businesspeople, a patent lawyer, and biotechnology companies, misappropriated trade secrets involving DNA encoding and decoding. They alleged two primary acts: the theft of trade secrets from a confidential grant proposal in 1994 and the misappropriation of files, including a set of 465 zip codes, in 1999.

The plaintiffs asserted claims under the federal Defend Trade Secrets Act, the Racketeer Influenced and Corrupt Organizations Act, New York trade-secret law, and several common-law theories, including fraud, conversion, tortious interference with prospective business advantage, inequitable conduct, civil conspiracy, and breach of confidence. They alleged that a twenty-five-year conspiracy concealed the wrongdoing until 2015 and that their August 2018 lawsuit was therefore timely.

Motions and Legal Standards

The defendants collectively moved to dismiss under Rules 12(b)(1) and 12(b)(6) of the Federal Rules of Civil Procedure. Rule 12(b)(1) concerns the court’s subject-matter jurisdiction, while Rule 12(b)(6) tests whether a complaint states a legally sufficient claim. Stephen Fodor also filed an individual motion to dismiss and joined the defendants’ motion.

The defendants argued that the plaintiffs lacked standing because they had assigned or developed their intellectual-property rights for Cornell University. The court explained that this issue was not constitutional standing but whether the plaintiffs had a cause of action under the applicable trade-secret laws. The court did not resolve that ownership issue on the motion because factual disputes remained about how the intellectual property was developed.

Statutes of Limitations

The court first addressed the statute of limitations. It held that the federal claims were subject to three- or four-year limitations periods. The court concluded that the plaintiffs were on actual, constructive, or inquiry notice of the alleged wrongdoing no later than events involving publicly available patent applications, the 2006 patent-interference proceedings, or the 2010 patent litigation concerning related patents.

The court therefore held that the federal claims were untimely whether the limitations period began in 1994, 1999, 2006, or 2010. The court similarly held that the New York claims were untimely. It stated that the state claims accrued when the alleged misconduct occurred or when the defendants first disclosed or used the alleged trade secrets, and that the applicable three- or six-year periods had expired.

The plaintiffs sought equitable tolling based on fraudulent concealment. Equitable tolling can extend a filing deadline when defendants concealed material facts, that concealment prevented timely discovery, and the plaintiff acted diligently. The court held that the plaintiffs had not pleaded fraudulent concealment with the particularity required by Rule 9(b). It also held that the public patent applications and prior patent proceedings showed that the plaintiffs had not acted with the required diligence. The court concluded that these deficiencies could not be cured by amendment.

Additional Federal-Claim Grounds

The court separately held that the federal claims failed because the alleged misappropriations occurred in 1994 and 1999, before the Defend Trade Secrets Act became effective on May 11, 2016. The court found no plausible allegation of relevant post-enactment conduct. It also concluded that the Racketeer Influenced and Corrupt Organizations Act claims failed to the extent they relied on alleged trade-secret misappropriation as predicate acts.

Trade-Secret Claims

The court held that the allegations concerning “negative trade secrets”—experimental information and unsuccessful efforts—were too vague and broad to identify the alleged secrets with sufficient specificity. The plaintiffs also did not adequately allege that this information had independent economic value because it was not generally known.

The court found that the plaintiffs described the 465-zip-code set with sufficient particularity but failed to allege that it had independent economic value from being secret, given the similar information publicly available in related patent materials. The court therefore held that the complaint failed to state misappropriation claims concerning the negative trade secrets and the 465-zip-code set. The court noted that the allegations about the 1994 grant proposal might have supported a timely trade-secret claim, but held that those claims were barred by the statute of limitations.

Other State-Law Claims

The court held that the fraud claims failed because the plaintiffs did not identify false statements or omissions on which they reasonably relied. The conversion claims failed because New York law does not allow conversion claims for intangible property such as ideas. The tortious-interference claims failed because the plaintiffs did not identify specific, ongoing business relationships with which the defendants interfered.

The court dismissed the inequitable-conduct claim because inequitable conduct before the Patent and Trademark Office is a defense to patent infringement, not an independent civil claim for damages. It dismissed the civil-conspiracy claim because New York does not recognize civil conspiracy as an independent tort and the underlying tort claims failed. It dismissed the breach-of-confidence claims because the alleged relationships were covered by express confidentiality agreements, leaving no basis for an independent implied-confidentiality tort.

Disposition

The court granted the defendants’ motions to dismiss and dismissed the complaint in its entirety with prejudice. Because the plaintiffs had already amended the complaint twice and further amendment would be futile, the court directed the Clerk to enter judgment dismissing the case with prejudice, close all pending motions, and close the case.